Investing in blistering capabilities to boost flexibility
Postponement printing is presenting interesting benefits for the pharmaceutical supply chain.
Global contract packaging organisation (CPO), Tjoapack has invested in its blistering capacity, adding a new line that will be equipped with late-stage customisation printing capabilities.
Expected to be operational by the end of Q3 2018, the new line, at the company’s facility in Etten-Leur, Netherlands, will take its total number of blistering lines to eight.
Tjoapack currently packs 26 million packs every year. This line will enable the company to offer another 4 million packs of additional capacity. "We’re optimising this line for flexibility and not for high volume throughput. It’ll be capable to handle a lot of different SKUs in smaller volumes, which is one of our areas of expertise," commented Dexter Tjoa, Director of Corporate Strategy at Tjoapack.
“At Tjoapack we’re committed to ensuring our customers continue to receive the efficient and flexible service that they’re used to, so we’re always looking for ways to further improve our operations to allow us to better cater for their projects.
“We have a strategic growth plan in place and increasing our blistering capacity will allow us to cater for increasing demand from both current and new customers.”
The investment will also expand Tjoapack’s current postponement printing offering, enabling the CPO to offer drop-on-demand digital printing for blisters.
The benefits of drop-on-demand and postponement printing
Drop-on-demand printing is used for late-stage customisation. "The idea is that stock remains market agnostic for as long as possible and then when demand for the product arises, companies can print directly onto blister packaging to meet the intended market requirements. In other words, stock is only being finalised as and when there is a requirement. This gives our customers' supply chains added flexibility to handle market-related fluctuations, reducing wastage and the need for rework at a later stage," explained Mr Tjoa.
He continued: "Postponement offers an increased level of flexibility to meet varying market demands, meaning it is easy to scale up and down your packaging for different markets. With the right set up, you could reduce your time-to-market and fulfilment cycles by several weeks, helping prevent stock-out scenarios, and assuring patients can receive the medicine they need on time.
"In addition, by keeping the product market-agnostic for as long as possible and by packing only when you need the product, you’re not only drastically reducing waste across the supply chain, but also minimising your working capital by reducing finished goods’ inventories and shortening your return-on-investment cycle.
“Late-stage customisation, or postponement printing, is presenting some interesting benefits for the pharmaceutical supply chain. The process of only making packaging market-specific once there is a demand could be hugely beneficial in terms of reducing waste from repackaging, overall costs and time to market.
“We’ve started to explore this type of packaging with some of our customers already and as more complex molecules continue to enter the drug pipeline, demand for last-minute packaging is likely to increase. This investment will allow us to futureproof our lines for projected demands.”
Up until now, postponement packaging remains relatively unexplored in the pharmaceutical industry. As companies look for ways to improve efficiencies, postponement packaging is something Tjoapack is increasingly seeing them consider. In addition, postponement is well suited to small volumes and as more personalised medicines enter the market, late-stage customisation could be an ideal way to handle these products.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance